BELOIT - NorthStar Medical Radioisotopes announced Tuesday construction on its Beloit production facility expansion is complete.
The company started construction on its 20,000-square-foot molybdenum-99 (mo-99) processing facility earlier this year.
Now comes equipment installation at the Beloit campus, and the expansion is set to establish the new processing facility as part of expanding current capacity and efficiency in radioisotope production and distribution.
NorthStar produces and distributes key radioisotopes used in a wide range of medical imaging tests.
CEO and President Stephen Merrick said the end of construction was a "significant marker" of the company's steady progress that culminated in receiving Food and Drug Administration (FDA) approval in 2018, making NorthStar the first domestic producer of non-uranium mo-99 in nearly 30 years.
"Construction completion of our Beloit, Wis. Mo-99 processing facility is a significant marker of NorthStar's progress, as we continue to execute on our plan to meet customer demand and ensure reliable, non-uranium based radioisotope supply for the U.S.," Merrick said. "We are grateful to Corporate Contractors Incorporated (CCI), the lead contractor for this complex construction project, for ensuring that the building handover has occurred on schedule, and installation of equipment for the facility is underway."
Merrick said the facility will enable double production for the company's patented RadioGenix System source vessels that are used by radiopharmacies.
Merrick said the company is working towards final validation of two fill lines at the company's Columbia, Missouri facility that, pending future FDA approval projected later this year, would increase the total number of source vessels that could be shipped weekly.